Peptide field guide
Lyngbyabellin Q
A marine cyanobacterial cyclic peptide natural product reported to disrupt actin dynamics and show potent in vitro antimalarial activity.
What it is
Lyngbyabellin Q is a cyclic peptide natural product reported in 2026 from a marine cyanobacterial biomat dominated by Moorena sp.
It belongs to the broader lyngbyabellin family of compounds (a natural-products lineage known for potent bioactivity).
Why people care about it
The interest here is two-sided:
- Anti-infective potency: the paper reports strong in vitro activity against Plasmodium falciparum.
- Mechanism risk signal: the compound is also reported to disrupt actin dynamics and inhibit mammalian cell growth, which can imply a narrow therapeutic window unless selectivity can be improved.
What we know vs what we do not know
What we know:
- Lyngbyabellin Q has been isolated and structurally characterized (per the publication).
- The authors report in vitro antimalarial activity (IC50 22 nM, in the abstract).
- The authors report actin disruption and HeLa growth inhibition.
What we do not know:
- In vivo efficacy in malaria models.
- Dose feasibility and safety margins.
- Whether analogs can reduce mammalian cytotoxicity while retaining antimalarial potency.
Latest updates
- 2026-03-27 (J Nat Prod): Two new lyngbyabellin analogs (Q and R) were reported from a Moorena-dominated biomat. Lyngbyabellin Q showed in vitro antimalarial activity (IC50 22 nM) and disrupted actin dynamics.
- https://pubmed.ncbi.nlm.nih.gov/41772786/ (doi:10.1021/acs.jnatprod.6c00068)
Safety reality
Lyngbyabellin Q is a research-stage natural product, not an approved medicine. Any non-regulated product claims should be treated as high risk.
References
Koyama R, et al. Lyngbyabellin Q, an Antimalarial Cyclic Peptide, and Its Acyclic Analog from a Cyanobacterial Biomat Dominated by Moorena sp. J Nat Prod. (2026). https://pubmed.ncbi.nlm.nih.gov/41772786/ doi:10.1021/acs.jnatprod.6c00068